bearish
Divi’s Laboratories - Miss in 2QFY23; Growth Factors to Face Softness over Medium Term
DIVI delivered an earnings miss in 2QFY23. Reduced traction in Custom Synthesis (CS), coupled with lower operating leverage resulted in an earnings decline for the first time
SUMMARY
(Sign Up to Access)Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
- Unlock research summaries
- Follow top, independent analysts
- Receive personalised alerts
- Access Analytics, Events and more
Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.
Upgrade later to our paid plans for full-access.
or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 22-minute read)
Related Insights
More »Loading
Trending Collections
More »Loading
Trending Insights
More »Loading
Top Unpaywalled Insights
More »Loading
Discussions
(Paid Plans Only)
Motilal Oswal
External broker reports(aggregated public sources)
Motilal Oswal Financial Services Limited
Price Chart(Sign Up to Access)
- Divi’s Laboratories - Miss in 2QFY23; Growth Factors to Face Softness over Medium Term12 Nov 2022
x